Horizon Therapeutics acquires Viela Bio in a $3.05B Deal to expand its rare disease portfolio

“This acquisition represents a significant step forward in advancing our strategy – to expand our pipeline in order to accelerate our growth over the long term.” - Tim Walbert, Horizon Chief Executive Officer

Deal Overview • Acquirer: Horizon Therapeutics plc (HZNP)

• Target: Viela Bio, Inc. (VIE) • Industry: Biopharmaceuticals

• Transaction Amount: $3.05B • Announcement Date: March 15, 2021

• Target Advisor: Goldman Sachs • Acquirer Advisor: Morgan Stanley

Horizon Therapeutics acquires Viela Bio

.

Download • 3.26MB